High-fat diet-induced kidney alterations in rats with metabolic syndrome: endothelial dysfunction and decreased antioxidant defense

Introduction: This study aimed to investigate changes in renal function and the AGE-RAGE axis in the kidney of a non-genetic animal model of metabolic syndrome (MetS) induced by high-fat diet (HFD). Additionally, we evaluated the protective effect of pyridoxamine (PM), a vitamin B6 analog with anti-AGE effects, in the context of diet-related renal endothelial dysfunction.

Methodology: In Wistar rats, the MetS animal model was induced by 20 or 28 weeks of HFD feeding. When indicated, a subgroup of animals was treated daily with PM (60 mg/kg) for 2 months. Tissue perfusion in renal microcirculation was examined by laser speckle contrast imaging. Oxidative stress was analyzed by thiobarbituric acid reactive species and the inflammatory markers by ELISA (TNF-α and IL-1β). Reverse transcription polymerase chain reaction was used to analyze eNOS, IL-6, vascular cell adhesion molecule (VCAM), NADPH oxidase subunit 47 (N47), catalase, and receptor for AGE (RAGE) gene expression.

Results: Wistar rats fed a HFD showed negligible alteration in renal function, decrease in catalase mRNA transcripts and catalase enzyme activity compared to control (CTL) animals. Increased levels of IL-1β were observed in the kidney of MetS-induced rats. HFD-fed rats exhibited kidney endothelial dysfunction, with no significant differences in basal microvascular blood flow. PM significantly improved kidney vasorelaxation in HFD-fed rats. eNOS, VCAM, and RAGE gene expression and AGE content were not altered in kidneys of HFD-induced MetS rats in comparison to CTLs.

Conclusions: Our findings suggest that HFD-induced microvascular dysfunction precedes the decline in renal function, and could be related to antioxidant machinery defects and inflammation activation in the kidney. PM showed a vasoprotective effect, and thus, could be an important contributory factor in ameliorating diet-induced renal damage.

Keywords: metabolic syndrome, kidney endothelial dysfunction, pyridoxamine, advanced glycation end products

Introduction

The metabolic syndrome (MetS) is a combination of metabolic conditions, comprising of elevated blood pressure, obesity, atherogenic dyslipidemia, and dysglycemia, associated with increased risk of type 2 diabetes and atherosclerotic cardiovascular disease.1,2 MetS is a recurrent public health problem with increasing prevalence during the last three decades, mainly due to the global spread of the Western lifestyle.3,4 Individuals with MetS are at high risk of developing chronic kidney disease (CKD), which is an independent risk factor for cardiovascular...
Also, one of the most frequent microvascular complications of diabetes is the diabetic nephropathy, which progresses to end-stage renal disease in one-third of patients with type 1 diabetes (T1DM) and 20% of the patients with type 2 diabetes (T2DM). Therefore, the prevention of renal alterations and/or CKD is critical to improve cardio-renal outcomes in MetS and diabetes patients. To develop a preventative strategy against CKD in these patients, it is essential to clarify renal alterations in MetS, including oxidative, inflammatory, and endothelial function status. However, these have not been yet thoroughly evaluated, and the mechanisms by which MetS may influence kidney dysfunction remain unclear.

Currently established therapeutic approaches for diabetic nephropathy are primarily antihypertensives that target the renin angiotensin aldosterone system, including angiotensin-converting enzyme inhibitors (iECA) and angiotensin II receptor blockers. These interventions appear to reduce or delay the proteinuria but do not prevent the establishment of end-stage renal disease. Therefore, the primary challenge is to identify pharmacological and non-pharmacological treatments that are able to prevent the progression of renal dysfunction.

Pyridoxamine (PM) is a vitamin B6 analog that exerts antiglycative effect. It has been proposed as supplementary approach in patients with renal diseases as it has demonstrated effectiveness in impairing the development of diabetic nephropathy, in both patients and experimental models of diabetes. PM is effective in inhibiting advanced glycation end products (AGE) or advanced lipoxidation end products (ALE) formation from Amadori adducts by trapping pathogenic reactive carbonyl intermediates of AGE/ALE formation. AGE/ALE are irreversible products expressed ubiquitously and overproduced in pathologies such as diabetes, CKD, Alzheimer disease, and non-alcoholic fatty liver disease. Additionally, PM has anti-inflammatory, antioxidant, and metabolic effects, which makes it a promising candidate for the management of MetS related renal alterations. However, the effect of PM on renal endothelial dysfunction due to high-fat diet (HFD)-induced MetS remains unveiled.

Large number of associative studies between MetS and renal ED are available; however, a causal relationship between them is not proven. The major factors contributing to endothelial dysfunction and/or renal damage in MetS and related diseases are increases in oxidative stress and inflammatory cytokines which could be due to (a) enlargement of white adipose tissue; (b) insulin resistance; (c) increase in TGL and FFA; (d) activation of AGE-RAGE axis; (e) increased angiotensin II production, and (f) hyperuricemia. Dissecting out the relative contribution of each of those mechanisms to MetS pathophysiology, however, is difficult. Since kidney endothelial dysfunction is a hallmark of MetS and has its physiopathology is not fully understood. Our study aims to investigate (a) selective inflammatory and pro-oxidant signaling pathways as possible participants in the physiopathology of MetS induced renal alterations and (b) whether PM treatment would exert renoprotective effects in renal endothelial dysfunction triggered by HFD consumption.

**Materials and methods**

**Animals and experimental protocol**

Twenty male Wistar rats (4 weeks of age) from the central animal facility of the Oswaldo Cruz Foundation, Brazil were housed in standard cages in a controlled environment (22±1°C temperature and 12 hrs, light/dark). MetS was induced in 10 animals by 20 weeks of feeding with a HFD consisted of a standard rat diet modified to contain 30% fat (lard), 56% carbohydrate, and 14% protein (% g) (Figure 1A). The non-MetS control (CTL) animals received standard rat diet (n=10) for 20 weeks. For the study of PM effect on endothelial dysfunction, twenty-four (24) Wistar rats were used, divided into three experimental groups: the non-MetS CTL animals, which received standard rat diet for 28 weeks (n=8), the HFD untreated animals, which received HFD for 28 weeks and were treated with vehicle between weeks 20–28 (HFD, n=9), and treated HFD-fed animals, which received PM (60 mg/kg/day, by gavage) also between weeks 20–28 (HFD + PM, n=7) (Figure 1B). Rats were provided with diet and water ad libitum. Animals under anesthesia were subjected to laser speckle contrast imaging (LSCI) evaluations, and then subjected to euthanasia by cardiac puncture. Total blood and kidney samples were collected and aliquots were stored at −80°C until measurement. Rats in each dietary group were placed in metabolic balance cages (Nalgene; Nalge Company, Rochester, NY, USA) for 24-hr urine collection to measure microalbuminuria and urine volume. All experiments were conducted according to the internationally accepted principles for the Care and Use of Laboratory Animals. Experimental protocols were approved by the Oswaldo Cruz Foundation Animal Welfare Committee (CEUA license L-034/2016).
Laser speckle contrast imaging (LSCI)

Kidney microvascular blood flow was measured by LSCI apparatus (Pericam PSI system, Perimed, Sweden).20,31 Overnight-fasted animals were anesthetized with ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p). Body temperature was continuously measured and maintained at 37.5°C by placing the animals on an electric heating pad (Harvard Apparatus, MA, United States) which adjust the body temperature in response to measured rectal temperatures. Left Kidney was exposed to laser light system for continuous measurement of tissue perfusion. Acetylcholine (Ach)(100 µL, 10−1 M) was applied directly on the kidney surface after 5 mins of microcirculatory flux stabilization. Relative kidney blood flow was expressed as arbitrary perfusion units.

Oxidative stress parameters

Lipid peroxidation in the kidney was assessed by measuring thiobarbituric acid reactive species as previously described.20 Catalase activity was determined in the kidneys by measuring the enzymatic decomposition of hydrogen peroxide at 240 nm.20

TNF-α and IL-1β measurements

TNF-α and IL-1β levels were measured in kidney samples with ELISA assay (R&D Systems, Minneapolis, USA).

Quantitative real-time polymerase chain reaction

Total RNA was extracted from the kidney using RNeasy Mini Kit (Qiagen), and reverse-transcribed to cDNA using a high capacity cDNA reverse transcription Kit (Applied Biosystems). The primers used for PCR amplification are described in Table 1. Real-time PCR was performed with the power SYBR Green PCR Master Mix (Applied Biosystems) using a 7500 real-time PCR system (Applied Biosystems). The expression of target genes was normalized to the expression of β-actin, and the ΔΔCt method was used for gene expression determination. Expressions of target genes are reported relative to endogenous beta-actin CTL.

Quantification of advanced glycation end products (AGE)

Fluorescent AGEs were determined at an emission and excitation wavelength of 440 and 370 nm, respectively on a
SpectraMax M5 ELISA Microplate Reader (Molecular Devices, CA, USA). AGE-specific fluorescence of the samples was measured at a protein concentration of 1 mg/mL and are expressed in AU compared with a native BSA solution (1 mg/mL, 0.1 N NaOH).

Statistical analysis
Results are expressed as the mean ± standard deviation (SD) for each group. Statistical analyses were performed with the Prism package. Student’s t-test was used for comparison of data of two groups. One-way ANOVA with Bonferroni’s post hoc test were used to determine the differences among three or more groups. Differences were considered significant at \( P<0.05 \).

Results
Metabolic, hemodynamic, and biochemical characterization of HFD-induced MetS rats were previously published in Pereira et al.\(^2\) Presently, we observed that HFD induced small but statistically significant alteration in renal function, as shown by increased levels of serum creatinine and decreased urine volume (Figure 2A and B, respectively).

The HFD-fed rats had higher serum uric acid levels than the CTL group (Figure 2C). However, biochemical analyses of 24-hr urine did not show evidence of microalbuminuria (data not shown).

Evaluation of oxidative stress parameters showed that HFD-fed rats presented decreased catalase mRNA transcripts and catalase enzyme activity in comparison to CTL animals (Figure 3A and C, respectively). Analysis of NADPH gene expression or MDA content in kidneys revealed no differences between groups (Figure 3B and D, respectively).

As shown in Figure 4A, kidneys of HFD-fed rats exhibited inflammation, as demonstrated by markedly increased IL-1\(\beta\). No significant changes were observed between groups in TNF-\(\alpha\) cytokine levels and IL-6 mRNA transcripts in kidneys (Figure 4B and C, respectively).

In order to evaluate if kidneys of HFD-induced MetS rats presented endothelial dysfunction, the basal and % of change in kidney microvascular flux after Ach administration were compared between groups (Figure 5). As shown in Figure 5A and C, kidneys of HFD-fed or HFD/MetS PM-treated animals exhibited no significant differences in basal

### Table 1 Primers used for PCR amplification

| Primer                        | Forward                        | Reverse                        |
|-------------------------------|--------------------------------|--------------------------------|
| NADPH oxidase p47 subunit (N47)| GTGAAGCCACATCGAGGTCATT       | CCGCGGCTTTTAACTGTT             |
| Endothelial nitric oxide synthase (eNOS)| GTATTTTGATGCTGGACTGG        | AGATTGCTCGGGTGTTG             |
| IL-6                           | AATCTGCTCTGCTTCTTGAGG        | GTTGATGCTGCTGCTGCTTAG         |
| VCAM                           | GCGAAGGAAACTGGGAAAGAACA     | ACCATGTAGGACCTGAGG            |
| Catalase (CAT)                 | ACTCAGTTGGCGAGACATTCC       | GGAGTGTCTGCTGCCAGAAGAGCC      |
| RAGE                           | CAGGCTCAGAGAAACCCG          | ATTCACGTGCAAGGTTTCCT           |
| beta-actin                     | CCACCGCAGTACACACCTT         | GAAGCCGCGCTTGCAATG            |

**Abbreviation:** VCAM, vascular cell adhesion molecule.

Figure 2 Renal function parameters in control (CTL) and HFD-fed rats (HFD/MetS) for 20 weeks. Serum creatinine (A), urinary volume (B), and serum uric acid (C).

\(^*\) \( P<0.05 \) vs control.

**Abbreviations:** CTL, control; HFD, high-fat diet; MetS, metabolic syndrome.
microvascular blood flow, irrespective of HFD duration. HFD-fed rats exhibited kidney endothelial dysfunction, as demonstrated by paradoxical vasoconstriction in response to Ach, while kidneys of control animals exhibited vasorelaxation at the same dose of Ach (Figure 5B and D, 20 and 28 weeks of HFD, respectively). Importantly, kidney vasorelaxation was marked and significantly improved when rats were treated with PM (Figure 5B and D, 20 and 28 weeks of HFD, respectively). Both eNOS and vascular cell adhesion molecule (VCAM) gene expression were not altered in the kidneys of HFD-induced MetS rats in comparison to CTLs (Figure 5E and F, respectively).

The participation of AGE-RAGE axis was evaluated in kidneys of HFD-induced MetS rats, and we have observed that there was no difference in the kidney AGE content and RAGE mRNA expression between the groups (Figure 6A and B, respectively).

**Discussion**

We have previously shown that Wistar rats fed a HFD for 20 weeks presented features of MetS, liver steatosis, and liver endothelial dysfunction. At present, we observed that HFD feeding induced paradoxical vasoconstriction in renal arteries at early-stages of renal disease, which to the best of our knowledge have not been previously explored. Paradoxical vasoconstriction, i.e., Ach mediated vasoconstriction, is a feature of patients with nonobstructive coronary atherosclerosis. It is believed that in atherosclerosis the lack of NO bioavailability triggers smooth muscle cell constriction leading to vasospasm in nonobstructive coronary arteries, which leads to myocardial infarction.

Classically, neutrophils and monocytes infiltrations, pro-inflammatory mediators as well as elevated oxidative stress are implicated the physiopathology of vascular damage, nonetheless, these cascades are still not proven participants of the paradoxical vasoconstriction phenomenon.

The increase in abdominal fat deposition, insulin resistance, and a pro-inflammatory and pro-oxidative environmental are well-accepted participants of the pathogenesis of endothelial dysfunction and contributes to the worsening of cardio-renal diseases. We demonstrated that HFD-induced MetS animals presented increased fat content and insulin resistance, as well as decreased antioxidant defense, evidenced by decrease in kidney catalase mRNA transcripts and...
activity, and increased pro-inflammatory cytokine IL-1β. The increase in the inflammatory mediator IL-1β in the kidneys is an indicator of tissue injury and danger signaling which triggers local and systemic inflammation through the activation of inflammasome. IL-1β has been implicated in the stimulation of leukocyte recruitment by activation of adhesion molecules, including intercellular adhesion molecule -1 and VCAM-1, which are implicated in the etiology of microcirculatory disturbances, finally leading to endothelial dysfunction.

Interestingly, despite having negligible changes in renal function, animals with MetS showed pronounced kidney microvascular endothelial dysfunction. Studies have shown that renal lesion (i.e., glomerulosclerosis) is present in obese patients with normal renal function evaluated by serum levels of plasma proteins, serum creatinine, and 24-hr proteinuria. Previously Pasarin et al, also showed the occurrence of endothelial dysfunction before the appearance of inflammation and fibrosis. In streptozotocin-induced diabetic rats, Maric-Bilkan and colleagues showed that microvascular changes preceded decline in renal function. Therefore, endothelial dysfunction could be an early-stage manifestation of MetS and related diseases and could have a causal role in the development of organ failure and/or CKD.

Increases in AGE levels were not observed in the kidney of 20 weeks HFD-induced MetS rats. Since we have previously shown that serum and liver AGEs levels are increased in animals with MetS it is plausible to think that macrophages and kupffer cells from the liver are actively participating in AGEs detoxification, generating low molecular weight soluble peptides which are further excreted by the kidneys. Over time, the loss of capacity of AGE detoxification and increased production of different types of AGE lead to a self-perpetuating cycle of AGE formation and oxidative stress which progressively increase renal injury.

PM has been recently proposed as a supplementary approach in diabetic nephropathy, due to its effect on reducing serum creatinine and/or urinary albumin/creatinine ratio in initial diabetic nephropathy. The therapeutic effects of PM to revert the vascular complication in MetS presently shown do not seem to depend on AGE-RAGE modulation and could be due to its antioxidant and metabolic effects. Jain and Lim reported that PM inhibits protein glycation, superoxide production, and lipid peroxidation. Improvement of body weight gain and glucose intolerance in HFD C57BL/6J or diabetic KK-AY/Ta mice was observed after PM treatment. Indeed, metabolic improvements associated with PM treatment in HFD-induced MetS rats

Figure 4 Inflammatory parameters assessed in the kidney of control group (CTL) and HFD-fed rats (HFD/MetS) for 20 weeks. Kidney levels of IL-1β and TNF-α (A and B, respectively) assessed by ELISA quantification and mRNA transcript levels of gene coding for IL-6 evaluated by RT-PCR (C). *P<0.05 vs control.

Abbreviations: CTL, control; HFD, high-fat diet; MetS, metabolic syndrome; RT-PCR, reverse transcription polymerase chain reaction.
were evidenced by our group including body weight (HFD 569.8 g ± 75.5 vs HFD + PM 492.7 g ± 31.6, \( P \leq 0.01 \)), fasting blood glucose (HFD 5.1 mmol/L ± 0.6 vs HFD + PM 4.2 mmol/L ± 0.4, \( P \leq 0.01 \)), and visceral fat recovery (HFD 18.8 g ± 5.1 vs HFD + PM 13.4 ± 1.5, \( P \leq 0.05 \)) (submitted paper). Mechanistically, the protective effect of PM could be due to increased expression of kidney and adipose tissue CD36, a receptor/transporter of fatty acids.\(^{47}\)

**Figure 5** Kidney endothelial function of control group (CTL), HFD-induced MetS rats (HFD/MetS) and MetS rats treated with 60 mg/kg/day pyridoxamine (PM) during the last 8 weeks of HFD feeding. Laser speckle contrast imaging (LSCI) assessment of basal microvascular flux (A and C, 20 and 28 weeks of HFD, respectively) and percentage (%) of change in kidney microvascular flux after topical acetylcholine (Ach) administration (B and D, 20 and 28 weeks of HFD, respectively). Real-time PCR analyses of mRNA transcript levels of genes coding for eNOS (E) and VCAM (F). **\( P \leq 0.001 \), ***\( P \leq 0.001 \) vs control and PM vs HFD/MetS.

**Abbreviations:** Ach, acetylcholine; CTL, control; HFD, high-fat diet; LSCI, laser speckle contrast imaging; MetS, metabolic syndrome; PM, pyridoxamine.
Our findings suggested that HFD-induced kidney microvascular dysfunction is an early manifestation of MetS and is related to antioxidant machinery defects and inflammation activation. Additionally, PM is a promissory agent in the management of MetS related kidney endothelial dysfunction, probably due to its metabolic and antioxidant effects. Our results reinforce the view that therapeutic strategies aimed at minimizing HFD-induced renal damage are especially necessary for MetS patients.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Grundy SM, Cleeman JL, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–2752. doi:10.1161/CIRCULATIONAHA.105.169404

2. Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016;26(4):364–373. doi:10.1016/j.tcm.2015.10.004

3. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12. doi:10.1007/s11906-018-0812-z

4. Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2017;960:1–17. doi:10.1007/978-3-319-48382-5_1

5. Nashar K, Egan BM. Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes Metab Syndr Obes. 2014;7:421–435. doi:10.2147/DMSO.S45183

6. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16(7):2134–2140. doi:10.1681/ASN.2005010106

7. Guo Y, Cui L, Ye P, Li J, Wu S, Luo Y. Change of kidney function is associated with all-cause mortality and cardiovascular diseases: results from the Kailuan study. J Am Heart Assoc. 2018;7(21):e010596. doi:10.1161/JAHA.118.008528

8. Zhai X, Lerman LO. Pyridoxamine dihydrochloride in diabetic nephropathy in KK-A(y)/Ta mice. Kidney Int. 2005;68(1):167–174. doi:10.1111/j.1523-1755.2002.00207.x

9. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341(15):1127–1133. doi:10.1056/NEJM199910073411506

10. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J. Therapeutic approaches to diabetic nephropathy—beyond the RAS. Nat Rev Nephrol. 2014;10(6):325–346. doi:10.1038/nrneph.2014.74

11. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007;27(6):605–614. doi:10.1159/000108104

12. Dwyer JP, Greco BA, Umanath K, et al. Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): lessons learned from a pilot study. Nephron. 2015;129(1):22–26. doi:10.1159/000369310

13. Tanimoto M, Gohda T, Kaneko S, et al. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism. 2007;56(2):160–167. doi:10.1016/j.metabol.2006.08.026

14. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 2002;61(3):939–950. doi:10.1046/j.1523-1755.2002.00207.x

15. Chiassa F, Cento AS, Collotta D, et al. Protective effects of pyridoxamine supplementation in the early stages of diet-induced kidney dysfunction. Biomed Res Int. 2017;2017:2682861. doi:10.1155/2017/2682861

16. Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci. 2005;62(15):1671–1681. doi:10.1007/s00018-005-5082-7

17. Metz TO, Alderson NL, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys. 2003;419(1):41–49. doi:10.1016/j.abb.2003.08.021

18. Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem. 2003;278(43):42012–42019. doi:10.1074/jbc.M304292200

19. Brings S, Fleming T, Freichel M, Muckenthaler MU, Herzig S, Nawrath PP. Dicarbonyls and advanced glycation end-products in the development of diabetic complications and targets for intervention. Int J Mol Sci. 2017;18(5). doi:10.3390/ijms18050984

20. Pereira E, Silvares RR, Flores EEI, et al. Hepatic microvascular dysfunction and increased advanced glycation end products are components of non-alcoholic fatty liver disease. PLoS One. 2017;12(6):e0179654. doi:10.1371/journal.pone.0179654

21. Taniguchi N, Takahashi M, Kizuka Y, et al. Glycation vs. glycosylation: a tale of two different chemistries and biology in Alzheimer’s disease. Glycoconj J. 2016;33(4):487–497. doi:10.1007/s10719-016-9690-2

22. Rabbani N, Thornalley PJ. Advanced glycation end-products in the pathogenesis of chronic kidney disease. Kidney Int. 2018;93(4):805–813. doi:10.1016/j.kint.2017.11.034

23. Maessen DE, Brouwers O, Gaens KH, et al. Delayed intervention therapy for treatment of diabetic complications. Diabetologia. 2018;61(5):956–966. doi:10.2337/db15-1390
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal

24. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6(10):2364–2373. doi:10.2215/CJN.02180311

25. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004;15(11):2792–2800. doi:10.1097/01.ASN.0000141966.69934.21

26. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111(11):1448–1454. doi:10.1161/01.CIR.0000158483.13093.9D

27. Prasad GV. Metabolic syndrome and chronic kidney disease: current status and future directions. World J Nephrol. 2014;3(4):210–219. doi:10.5527/wjn.v3.i4.210

28. Stirban A, Gawlowski T, Roden M. Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms. Mol Metab. 2014;3(2):94–108. doi:10.1016/j.molmet.2013.11.006

29. Cao Z, Cooper ME. Role of angiotensin II in tubulointerstitial injury. Semin Nephrol. 2001;21(6):554–562.

30. Wang H, Zhang H, Sun L, Guo W. Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases. Am J Transl Res. 2018;10(9):2749–2763.

31. Wu Y, Ren J, Zhou B, et al. Laser speckle contrast imaging for measurement of hepatic microcirculation during the sepsis: a novel tool for early detection of microcirculation dysfunction. Microvasc Res. 2015;97:137–146. doi:10.1016/j.mvr.2014.10.006

32. Nakayama H, Mitsushashi T, Kuwajima S, et al. Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rat. Diabetes. 1993;42(2):345–350. doi:10.2337/dbi.42.2.345

33. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315(17):1046–1051. doi:10.1056/NEJM198610233151702

34. Niccoli G, Scalone G, Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management. Eur Heart J. 2015;36(8):475–481. doi:10.1093/eurheartj/ehu449

35. Nguyen MT, Pham I, Valensi P, et al. Flow-mediated-paradoxical vasoconstriction is independently associated with asymptomatic myocardial ischemia and coronary artery disease in type 2 diabetic patients. Cardiovasc Diabetol. 2014;13:20. doi:10.1186/1475-2840-13-80

36. Sun CK, Shao PL, Wang CJ, Yip HK. Study of vascular injuries using endothelial denudation model and the therapeutic application of shock wave: a review. Am J Transl Res. 2011;3(3):259–268.

37. Engin A. Endothelial dysfunction in obesity. Adv Exp Med Biol. 2017;960:345–379. doi:10.1007/978-3-319-48382-5_15

38. Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol. 2017;70(18):2278–2289. doi:10.1016/j.jacc.2017.09.028

39. Serra A, Romero R, Lopez D, et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 2008;73(8):947–955. doi:10.1016/j.kint.2007.02.079

40. Chang Y, Ryu S, Cho J, Pastor-Barriuso R, Guallar E. Metabolically healthy obesity and development of chronic kidney disease. Ann Intern Med. 2016;165(10):744–745. doi:10.7326/L16-0405

41. Pasarin M, La Mura V, Gracia-Sancho J, et al. Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PLoS One. 2012;7(4):e32785. doi:10.1371/journal. pone.0032785

42. Marie-Bilkan C, Flynn ER, Chade AR. Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat. Am J Physiol Renal Physiol. 2012;302(3):F308–F315. doi:10.1152/ajprenal.00421.2011

43. Chade AR. Small vessels, big role: renal microcirculation and progression of renal injury. Hypertension. 2017;69(4):551–563. doi:10.1161/HYPERTENSIONAHA.116.08319

44. Sanajou D, Ghorbani Haghiyo A, Argani H, Aslan S. AGE-RAGE axis blockade in diabetic nephropathy: current status and future directions. Eur J Pharmacol. 2018;833:158–164. doi:10.1016/j.ejphar.2018.06.001

45. Jain SK, Lim G. Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic Biol Med. 2001;30(3):232–237.

46. Hagiwara S, Gohda T, Tanimoto M, et al. Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet 7BL/6J mice. Metabolism. 2009;58(7):934–945. doi:10.1016/j. metabol.2009.02.033

47. Murakoshi M, Tanimoto M, Gohda T, et al. Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. Mol Metab. 2009.3(4):e32785. doi:10.1016/j.molmet.2009.02.033

48. Murphy SL, Desai MR, Chade AR, et al. Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. Diabetologia. 2009;52(12):2378–2379. doi:10.1007/s00125-009-1288-7

49. Bou Gloud A, Amplification of pyridoxamine metabolites alteration in a transgenic model of type 1 diabetes. Mol Metab. 2014.3(4):e32785. doi:10.1016/j.molmet.2013.11.006

50. Cao Z, Cooper ME. Role of angiotensin II in tubulointerstitial injury. Semin Nephrol. 2001;21(6):554–562.

51. Wang H, Zhang H, Sun L, Guo W. Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases. Am J Transl Res. 2018;10(9):2749–2763.

52. Wu Y, Ren J, Zhou B, et al. Laser speckle contrast imaging for measurement of hepatic microcirculation during the sepsis: a novel tool for early detection of microcirculation dysfunction. Microvasc Res. 2015;97:137–146. doi:10.1016/j.mvr.2014.10.006

53. Nakayama H, Mitsushashi T, Kuwajima S, et al. Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rat. Diabetes. 1993;42(2):345–350. doi:10.2337/dbi.42.2.345

54. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315(17):1046–1051. doi:10.1056/NEJM198610233151702

55. Niccoli G, Scalone G, Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management. Eur Heart J. 2015;36(8):475–481. doi:10.1093/eurheartj/ehu449

56. Nguyen MT, Pham I, Valensi P, et al. Flow-mediated-paradoxical vasoconstriction is independently associated with asymptomatic myocardial ischemia and coronary artery disease in type 2 diabetic patients. Cardiovasc Diabetol. 2014;13:20. doi:10.1186/1475-2840-13-80